Archives

Gratifii Limited (GTI) has issued 72,062,500 two-year options with an exercise price of $0.10, completing the second tranche of a capital raise that received shareholder approval on 13 July 2026. The options were issued on 20 July 2026 as part of a placement approved by the market and are not quoted on the ASX. The issuance expands the company's unquoted securities portfolio and provides investors with additional conversion opportunities into ordinary shares.

• July 21, 2026 03:14 PM AEST
• Anjali Anand

Lynas Rare Earths is trading below a widely cited estimate of its intrinsic worth even as demand for the magnet metals used in electric drivetrains, wind turbines and defence hardware firms. This piece unpacks why the shares screen cheap, how the value case blends with a structural growth theme, and the key assumptions the apparent discount ultimately rests on. Tickers used:ASX:LYC Alternate headline 1:Is This ASX Rare Earths Name Trading Below Its Worth? Alternate headline 2:Magnet-Metal Demand Puts an ASX Producer on Value Radars

• July 21, 2026 03:10 PM AEST
• Sam

Telix faces a radiopharma proof test as imaging adoption, regulatory progress, manufacturing reliability, reimbursement access and cash discipline shape confidence in its commercial healthcare platform.

• July 21, 2026 03:10 PM AEST
• Sam

Gratifii Limited (GTI) has completed the issuance of 52,937,482 unquoted two-year options with an exercise price of $0.10 per share, following shareholder approval on 13 July 2026. The options were issued on 20 July 2026 as part of the company's Tranche 1 capital raise and are not intended to be quoted on the ASX. The issuance represents a significant expansion of the company's unquoted securities portfolio and provides potential dilution pathways for the company's ordinary shareholder base.

• July 21, 2026 03:09 PM AEST
• Mukul

CSL remains in focus as margin recovery, product mix, plasma efficiency and disciplined execution shape confidence in the company and Australia’s broader healthcare sector during a selective market environment.

• July 21, 2026 03:09 PM AEST
• Sam

Pro Medicus remains in focus as contract execution, clinical workflow, hospital demand, recurring software use and disciplined expansion shape Australia’s healthcare technology discussion through a selective market cycle.

• July 21, 2026 03:09 PM AEST
• Sam

FBR Limited (ASX:FBR), a robotic technology company based in Western Australia, has announced a convertible note financing arrangement with SBC Global Investment Fund. The company will receive an initial commitment of AUD$900,000 through two tranches of AUD$450,000 each, with potential for a further AUD$2.97 million in subsequent drawdowns. The facility provides FBR with capital for operational expenses and working capital requirements while maintaining a relatively low dilutionary impact on existing shareholders.

• July 21, 2026 03:02 PM AEST
• Mukul

Vertex Minerals Limited (ASX: VTX) has extended the closing date for its Share Purchase Plan from 22 July 2026 to 27 July 2026, providing eligible shareholders additional time to participate in the capital raising. The plan offers qualified investors the opportunity to subscribe for up to $30,000 worth of shares at $0.10 per share, a discount to recent market prices. The extension underscores the company's commitment to broadening shareholder participation in its funding initiative as it advances gold production at its flagship Reward Gold Mine in New South Wales.

• July 21, 2026 02:50 PM AEST
• Shwetambri Chauhan

VRX Silica Limited (ASX:VRX) has completed a capital raise of $4,547,939 through the issue of 133,762,940 fully paid ordinary shares at $0.034 per share to sophisticated investors. The placement, executed on 20 July 2026, was conducted without disclosure requirements under Part 6D.2 of the Corporations Act. The company has issued a Section 708A(5)(e) notice to the ASX confirming compliance with applicable regulatory provisions.

• July 21, 2026 02:49 PM AEST
• Mukul

FBR Ltd has issued 1,910,526 unquoted options expiring on 21 July 2029 with an exercise price of $0.17 per share as part of a convertible note funding arrangement announced on 20 July 2026. The options represent a non-cash component of the company's capital raise, issued on a post-consolidation basis. The development follows FBR's placement or other type of issue previously disclosed to the ASX market.

• July 21, 2026 02:44 PM AEST
• Aakashdeep